Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
6-1-2021

Examination of a blood-brain barrier targeting β-galactosidase-galactosidasemonoclonal antibody fusion protein in a murine model of
GM1-gangliosidosis
Michael J Przybilla
University of Minnesota

Christine Stewart
Tanabe Research Laboratories U.S.A., Inc

Timothy W Carlson
University of Minnesota

Li Ou
University of Minnesota

Brenda L Koniar
University of Minnesota

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Przybilla, Michael J; Stewart, Christine; Carlson, Timothy W; Ou, Li; Koniar, Brenda L; Sidhu, Rohini; Kell,
Pamela J; Jiang, Xuntian; Jarnes, Jeanine R; O'Sullivan, M Gerard; and Whitley, Chester B, ,"Examination of
a blood-brain barrier targeting β-galactosidase-monoclonal antibody fusion protein in a murine model of
GM1-gangliosidosis." Molecular Genetics and Metabolism Reports. 27,. . (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10249

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Michael J Przybilla, Christine Stewart, Timothy W Carlson, Li Ou, Brenda L Koniar, Rohini Sidhu, Pamela J
Kell, Xuntian Jiang, Jeanine R Jarnes, M Gerard O'Sullivan, and Chester B Whitley

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/10249

Molecular Genetics and Metabolism Reports 27 (2021) 100748

Contents lists available at ScienceDirect

Molecular Genetics and Metabolism Reports
journal homepage: www.elsevier.com/locate/ymgmr

Examination of a blood-brain barrier targeting β-galactosidase-monoclonal
antibody fusion protein in a murine model of GM1-gangliosidosis
Michael J. Przybilla a, *, Christine Stewart b, Timothy W. Carlson c, Li Ou a, Brenda L. Koniar d,
Rohini Sidhu e, Pamela J. Kell e, Xuntian Jiang e, Jeanine R. Jarnes f, M. Gerard O’Sullivan c,
Chester B. Whitley a
a

Gene Therapy Center, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA
Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA
Comparative Pathology Shared Resource, University of Minnesota Masonic Cancer Center, Saint Paul, MN, USA
d
Center for Translational Medicine, Academic Health Center, University of Minnesota, Minneapolis, MN, USA
e
Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA
f
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
b
c

A R T I C L E I N F O

A B S T R A C T

Keywords:
GM1-gangliosidosis
Enzyme replacement therapy
Fusion enzyme

GM1-gangliosidosis is a lysosomal disease resulting from a deficiency in the hydrolase β-galactosidase (β-gal) and
subsequent accumulation of gangliosides, primarily in neuronal tissue, leading to progressive neurological
deterioration and eventually early death. Lysosomal diseases with neurological involvement have limited noninvasive therapies due to the inability of lysosomal enzymes to cross the blood-brain barrier (BBB). A novel
fusion enzyme, labeled mTfR-GLB1, was designed to act as a ferry across the BBB by fusing β-gal to the mouse
monoclonal antibody against the mouse transferrin receptor and tested in a murine model of GM1-gangliosidosis
(β-gal− /− ). Twelve hours following a single intravenous dose of mTfR-GLB1 (5.0 mg/kg) into adult β-gal− /− mice
showed clearance of enzyme activity in the plasma and an increase in β-gal enzyme activity in the liver and
spleen. Long-term efficacy of mTfR-GLB1 was assessed by treating β-gal− /− mice intravenously twice a week with
a low (2.5 mg/kg) or high (5.0 mg/kg) dose of mTfR-GLB1 for 17 weeks. Long-term studies showed high dose
mice gained weight normally compared to vehicle-treated β-gal− /− mice, which are significantly heavier than
heterozygous controls. Behavioral assessment at six months of age using the pole test showed β-gal− /− mice
treated with mTfR-GLB1 had improved motor function. Biochemical analysis showed an increase in β-gal enzyme
activity in the high dose group from negligible levels to 20% and 11% of heterozygous levels in the liver and
spleen, respectively. Together, these data show that mTfR-GLB1 is a catalytically active β-gal fusion enzyme in
vivo that is readily taken up into tissues.
Despite these indications of bioactivity, behavior tests other than the pole test, including the Barnes maze,
inverted screen, and accelerating rotarod, showed limited or no improvement of treated mice compared to
β-gal− /− mice receiving vehicle only. Further, administration of mTfR-GLB1 was insufficient to create measur
able increases in β-gal enzyme activity in the brain or reduce ganglioside content (biochemically and
morphologically).

1. Introduction
Lysosomal diseases are a group of rare, inherited, metabolic disor
ders that are caused by deficiencies in lysosomal proteins, leading to the
accumulation of their cellular substrates within the lysosome. Numerous
therapeutics have been developed and tested for treating lysosomal
diseases, including enzyme replacement therapy (ERT). However, due to

their size, lysosomal enzymes are unable to cross the blood-brain barrier
(BBB), limiting their effect on the neurological pathology. For this
reason, ERT has not been developed for many lysosomal diseases,
including GM1-gangliosidosis, which has widespread neurological
involvement.
GM1-gangliosidosis results from a deficiency in the lysosomal hy
drolase β-galactosidase (β-gal; E.C. 3.2.1.23), encoded by the GLB1 gene.
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β-gal is responsible for the cleavage of terminal β-galactose residues on
GM1 and GA1 gangliosides, which are a major component of the central
nervous system (CNS). Patients with the most severe form of the disease,
the infantile form, exhibit progressive neurodegeneration, including
profound hypotonia and weakness, global developmental delay, and
skeletal abnormalities. These patients typically never learn to ambulate
by crawling or walking. Most patients succumb to the disease by three
years of age [1,2]. Patients with the late-infantile and juvenile pheno
types usually learn to walk, but develop ataxia in early childhood and
eventually become non-ambulatory. Death commonly occurs in early to
mid-childhood in the late-infantile phenotype and in mid- to latechildhood in the juvenile phenotype [3]. Currently, there are no clini
cally approved treatments for GM1-gangliosidosis.
ERTs have been developed for many lysosomal diseases (reviewed in
[4,5]) and high dose ERTs have shown efficacy in achieving neurological
benefits in animal models [6]; however, none are currently approved for
treating GM1-gangliosidosis. Preclinical experiments using purified [7]
and recombinant [8] feline β-gal have been tested in vitro as potential
therapies for GM1-gangliosidosis, though neither were utilized in animal
models of the disease to test efficacy. More recently, Condori et al. [9]
developed and tested a recombinant human β-gal-fusion protein that
utilized the non-toxic lectin subunit ribosome-inactivating toxin B (RTB)
of ricin from Ricinus communis as a protein carrier across the BBB. Pre
viously, fusion of RTB to the deficient protein in the lysosomal disease
mucopolysaccharidosis type I (MPS I) has shown the ability of delivering
the enzyme, α-L-iduronidase (IDUA), to the brain in a murine model of
the disease [10]. In vitro experiments with β-gal:RTB showed that the
fusion protein was internalized into human fibroblasts, processed into
the mature form of β-gal, was catalytically active, and reduced gangli
oside content [9]. Recently, Acosta and Cramer [11] described in their
review of lectin-mediated delivery of macromolecules into the CNS that
intravenous administration of β-gal:RTB into β-gal− /− mice resulted in
measurable β-gal enzyme activity in the CNS and mature β-gal protein in
the cerebellum and spinal cord of treated mice. However, no data was
presented.
An alternative platform for engineering lysosomal enzymes for
crossing the BBB has been developed, which utilizes genetic fusion of the
lysosomal enzyme to antibodies [12]. For lysosomal diseases, the lyso
somal enzyme is fused to a monoclonal antibody against either the
human insulin receptor (HIR) or the mouse transferrin receptor (mTfR).
For multiple lysosomal diseases, this approach has been utilized in
murine experiments, including MPS I (Hurler syndrome) [13], MPS II
(Hunter syndrome) [14,15] and MPS IIIA (Sanfilippo syndrome type A)
[16]. Additionally, preliminary safety studies in mice have been pre
sented for metachromatic leukodystrophy [17]. In MPS I mice, one hour
following intravenous (IV) administration revealed an increase in α-Liduronidase enzyme activity in the liver, spleen, heart, kidney, serum,
and brain of treated mice [13]. Following eight weeks of injections, the
level of glycosaminoglycans (GAG) was reduced in the liver, spleen, and
heart of treated mice, but not in the kidney or brain, though there was a
73% reduction in the inclusion bodies in the brain. [13]. Following six
weeks of intraperitoneal (IP) administration of the fusion protein in MPS
IIIA mice, the GAG heparan sulfate was significantly reduced in the
brain and liver of treated mice, whereas the GAG dermatan sulfate was
only reduced in the liver [16]. Further, motor function assessment uti
lizing the rotarod showed mice treated with the MPS IIIA fusion protein
performed better than sham-treated mice. However, treated animals
were not compared to normal mice. Further, studies in rhesus macaques
show that these fusion enzymes are capable of penetrating the BBB and
are safe for repeated IV injections [18,19]. Results from these studies led
to their use in two clinical trials for MPS I and MPS II (Clinical Trial
Identifiers MPS I: NCT03071341; MPS II: NCT02262338). For MPS I, the
results of the phase 1/2 clinical trial showed that 52 weeks of IV treat
ment with the enzyme valanafusp alpha was well tolerated, with the
primary adverse reactions being infusion reactions and mild hypogly
cemia [20]. Further, neurological scores of patients and CSF levels of the

GAGs heparan and dermatan sulfate were stable during the study.
However, the study did not compare enrolled patients to a control group
or natural history data of the MPS I disease, limiting the interpretation of
the efficacy of this fusion protein.
In the present study, a novel lysosomal enzyme fusion protein, mTfRGLB1, was tested as a therapy for GM1-gangliosidosis in β-gal deficient
mice (β-gal− /− ). mTfR-GLB1 is a fusion of the human β-gal enzyme to the
carboxyl terminus of each heavy chain of a mouse chimeric monoclonal
antibody against the mouse transferrin receptor (mTfR); therefore, each
mTfR-GLB1 molecule contains two human β-gal enzymes with a mo
lecular weight of 292 kDa. This study aimed to test the efficacy of longterm intravenous administration of mTfR-GLB1 to determine whether
this novel fusion enzyme could be utilized as a therapeutic agent for
treating GM1-gangliosidosis and preventing the onset of the neurolog
ical symptoms and pathology previously described in the murine model
of GM1-gangliosidosis [21].
2. Materials and methods
2.1. Expression and purification of mTfR-GLB1
mTfR-GLB1 was designed and synthesized using established meth
odologies for monoclonal antibody-lysosomal enzyme fusion proteins
[12,13,16–19,22–24]. Briefly, a plasmid encoding the sequence of
mTfR-GLB1 was expressed in stable Chinese hamster ovary cells. The
supernatant was removed and purified utilizing Protein A purification
(HiTrap® MabSelect SuRe™, Cytiva Life Sciences, Marlborough, MA).
The final formulation buffer (or vehicle) was adjusted to 25 mM citrate,
150 mM NaCl, pH 6.0.
2.2. Animals and procedures
All animal care and experimental procedures were conducted under
the approval of the Institute Animal Care and Use Committee (IACUC) of
the University of Minnesota. All animals were housed in specific
pathogen-free conditions.
GM1-gangliosidosis mice (β-gal− /− ) were generated by targeted
knockout of 20 bp in exon 8 of the β-gal encoding gene, Glb1 [21]. All
animals were genotyped by PCR. For short-term assessment, two to sixmonth-old mice received a single intravenous injection of mTfR-GLB1 at
a dose of 5 mg of mTfR-GLB1 (molecular weight) per kilogram of body
weight (mg/kg) through the lateral tail vein and euthanized after 12 h.
For the long-term efficacy study, eight-week-old mice (n = 12 per group;
n = 6 of each sex) were injected intravenously through the lateral tail
vein twice per week with a dose of 2.5 or 5.0 mg/kg of mTfR-GLB1 or
empty vehicle for 17 weeks. Volume was adjusted to 200 μl for each
injection with vehicle buffer. Following injection of mTfR-GLB1, ani
mals were monitored for at least one hour for potential adverse events,
including lethargy, respiratory changes, or other abnormal behavior. If
mice had an adverse reaction that lasted 30 min or longer, a 10 mg/kg
dose of diphenhydramine was administered intraperitoneally (IP). Ani
mals which received diphenhydramine were then given prophylactic
diphenhydramine for the duration of the study. Mice were monitored
daily for signs of morbidity and mortality, in addition to weekly weights
for signs of toxicity to mTfR-GLB1.
For biochemical analysis, animals were sacrificed by CO2 asphyxia
tion and perfused via transcardial perfusion with 20 ml of ice-cold
phosphate-buffered saline. Tissues isolated for biochemical assays
were flash frozen in liquid nitrogen and stored at − 80 ◦ C until assayed.
2.3. β-Galactosidase (β-gal) enzyme assay
β-gal enzyme activity was determined utilizing a fluorometric assay
using
4-methylumbelliferyl-β-D-galactopyranoside
(4-MUGal,
Millipore-Sigma, St. Louis, MO) as the substrate as previously described
[21]. β-gal enzyme activity was expressed in nmol of 4-MU released per
2
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hour, per milligram of protein (nmol/h/mg). Total protein quantifica
tion was determined using a Pierce™ 660 nm Protein Assay Kit (Thermo
Fisher Scientific, Waltham, MA).

time continued until 60 s. Mice were subjected to a single trial.
2.6.1.3. Rotarod. Rotarod analysis was conducted on an accelerating
rotarod (Ugo Basile, Comerio, Italy), using an adapted protocol
described previously [27]. Briefly, mice were tested for three consecu
tive days, undergoing four trials per day, with a minimum inter-trial
duration of 30 min. Testing was done on a rotarod programmed to
accelerate from 5 to 50 rpm over a max trial duration of 300 s. Three to
five mice were placed on the divided rod simultaneously, and the
apparatus’ counter was started. The trial was considered complete when
1) the mouse fell off the rotarod and stopped the counter, 2) the mouse
completes two consecutive rotations by holding on to the rod without
walking, or 3) when 300 s elapsed.

2.4. Histopathological analysis
Following perfusion and fixation with 10% NBF, tissues were pro
cessed into paraffin wax using standard histology techniques, sectioned
at a thickness of 4 μm, stained with hematoxylin and eosin (H&E), and
evaluated using light microscopy by two A.C.V.P. board-certified pa
thologists (T.C. and M.G.O’S). Additional evaluation was performed on
selected tissues stained with Luxol fast blue (LFB)/H&E combination
stain using standard laboratory protocols. All work was done at the
Masonic Cancer Center Comparative Pathology Shared Resource labo
ratory at the University of Minnesota.

2.6.2. Neurocognitive testing
2.6.2.1. Barnes maze. The Barnes maze [28] was conducted on an
elevated circular platform, 36 in. in diameter, with 20 equally spaced
holes around its perimeter. All of the holes on the platform were blocked
except for one, which contained an opening to an escape box. The
apparatus was placed directly under a bright light source that served as
an aversive stimulus for the mouse to escape the platform. Visual cues
were placed on each of the walls that act as navigational cues for the
mouse. Mice were trained on the Barnes maze for four days, with each
mouse subjected to four trials per day, with a max of 3 min per trial, and
a minimum of 30 min between trials. Data was collected utilizing the
ANY-Maze software (Stoelting Co, Wood Dale, IL).

2.5. Ganglioside isolation and quantification
GM1 and GA1 ganglioside levels were quantified as previously
described [21]. The mouse hippocampus, cerebellum, and cerebral
cortex tissues were homogenized in 2% CHAPS solution (40 ml/g for
hippocampus and cerebellum tissues; 10 ml/g for cerebral cortex tissue).
Protein precipitation with 200 μl of methanol was performed to extract
GM1 and GA1 from 50 μl of homogenate in the presence of internal
standards (d3-GM1(18:0) for GM1 and d3-GA1(18:0) for GA1). The 10%
study sample extracts from each tissue type were pooled to prepare a
quality control (QC) sample for that tissue. The QC samples were
injected every 10 study samples to monitor the instrument performance.
Sample analysis was performed with a Shimadzu 20 CE HPLC system,
coupled to a 6500QTRAP+ mass spectrometer (AB Sciex, Framingham,
MA) operated in positive MRM mode. Data processing was conducted
with Analyst 1.6.3 (Applied Biosystems). The relative quantification of
lipids is provided, and the data were reported as the peak area ratios of
the analytes to the corresponding internal standards.

2.7. Statistical analysis
GraphPad Prism 8 (v. 8.4.2, GraphPad Software, Inc) was used to
perform all statistical analyses. For enzyme activity, pole test, and
inverted screen behavior tests, a one-way ANOVA, followed by Dun
nett’s multiple comparisons test was used. For weight and plasma β-gal
enzyme activity, a repeated-measures two-way ANOVA, followed by
Tukey’s multiple comparisons test, was performed. For ganglioside
quantification, the accelerating rotarod, and Barnes maze, a two-way
ANOVA, followed by Tukey’s multiple comparisons test was used. Sig
nificance cutoff of p < 0.05 was used. All values are presented as mean ±
SEM.

2.6. Mouse behavior analysis
Beginning at approximately 24 weeks of age, corresponding to week
15 of mTfR-GLB1 injections, mice were subjected to a battery of
behavior tests to assess neuromotor and neurocognitive function. All
behavioral analyses were conducted in the Mouse Behavior Core at the
University of Minnesota.

3. Results

2.6.1. Neuromotor testing

3.1. Catalytic activity of mTfR-GLB1 in vivo

2.6.1.1. Inverted screen. Inverted screen testing [25] was completed
utilizing a wire mesh apparatus, approximately 25 cm × 25 cm with 25
mm2 square openings, placed approximately 30 cm over a cushioned
surface. Testing began by placing the mouse on the wire mesh, which
was then inverted until the animal was completely upside down. Latency
to fall was measured for a max trial duration of 120 s. Mice were sub
jected to three trials, with a minimum of a 15-min resting period be
tween trials.

Preliminary experiments conducted prior to this study comparing
purified mTfR-GLB1 to recombinant human β-gal enzyme (hβ-gal)
revealed that mTfR-GLB1 had approximately 17% of hβ-gal enzyme
activity in vitro, when using molecular weight equivalencies (Tanabe
Research Laboratories, personal communication). When translated to
percent of β-gal enzyme activity per mole of β-gal, mTfR-GLB1 has
approximately 34% of hβ-gal enzyme activity. To test the function of
mTfR-GLB1 in vivo, a short-term experiment was conducted. Two to sixmonth old β-gal− /− mice were injected with 5.0 mg of mTfR-GLB1 per
kilogram body weight (mg/kg) of mTfR-GLB1 (n = 4) or vehicle only (n
= 3) IV through the lateral tail vein. Twelve hours following injection,
mice were euthanized and β-gal enzyme activity was measured in the
plasma, brain, heart, liver, spleen, and kidney. β-gal enzyme activity was
not present in the plasma of treated β-gal− /− mice, suggesting that the
enzyme was readily taken up into the peripheral tissue within 12 h
(Fig. 1A). In the liver, β-gal enzyme activity was increased approxi
mately 12-fold in mTfR-GLB1 treated β-gal− /− mice (46.02 ± 4.95 nmol/
h/mg protein) compared to vehicle only β-gal− /− mice (3.86 ± 0.38),
resulting in approximately 38% of heterozygous (n = 4) β-gal enzyme
activity (Fig. 1B). While not statistically significant (p = 0.0692), β-gal

2.6.1.2. Pole test. The pole test was conducted as previously described
with minor modifications [26]. The test began by placing a mouse headupward on a vertical pole (2 cm in diameter; 55 cm tall) wrapped in
athletic tape to assist with grip. Two measurements were taken: latency
to rotate body to face downward was measured, and the total time to
complete the turn and descend the pole and place all four paws on the
base of the apparatus inside of the cage (i.e. total time to complete the
test). Maximum test duration was set at 60 s. If a mouse failed to make
the initial rotation to face downward, 60 s was recorded for both the turn
and total time to complete the task. If the mouse fell from the pole during
the testing time, it was placed back at the initial starting point while the
3
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Fig. 1. β-galactosidase enzyme activity 12-h post-injection with mTfR-GLB1.

enzyme activity was increased 8.5-fold in the spleen of mTfR-GLB1
treated mice (38.67 ± 6.3) compared to β-gal− /− mice receiving
vehicle only (4.57 ± 0.21) (Fig. 1C). This was approximately 18% of
heterozygous β-gal enzyme activity. Surprisingly, β-gal enzyme activity
was not increased above β-gal− /− mice receiving vehicle only in the
brain, heart, or kidney (Fig. 1D, E, F). Overall, these results showed that
mTfR-GLB1 was readily taken up into the tissue and was catalytically
active in a murine model of GM1-gangliosidosis.
Two to six-month-old β-gal− /− mice were injected intravenously
with 5.0 mg/kg of mTfR-GLB1 (n = 4) or empty vehicle (n = 3). Control
heterozygous β-gal+/− mice (n = 4) were also treated IV with empty
vehicle. 12-h following treatment, animals were euthanized and β-gal
enzyme activity was measured in the (A) plasma, (B) liver, (C) spleen,
(D) brain, (E) heart, and (F) kidney. Mean ± SEM. ***p < 0.001 when
comparing mTfR-GLB1 treated β-gal− /− mice to vehicle only β-gal− /−
mice. One-way ANOVA with adjustments for multiple comparisons.

randomly assigned into one of six experimental groups (Table 1). Two
groups served as baseline controls for ganglioside quantification, which
included six heterozygous mice (β-gal+/− ) and six β-gal− /− mice, with
equal numbers of females and males. These mice were euthanized and
analyzed at eight weeks of age. The four remaining groups included two
control groups, β-gal+/− and β-gal− /− mice receiving vehicle only, one
group of β-gal− /− receiving a low dose of mTfR-GLB1 (2.5 mg/kg) and
another group of β-gal− /− mice receiving a high dose of mTfR-GLB1 (5.0
mg/kg). Each group consisted of eight female and eight male mice,
resulting in a total of 16 animals in each group. Injections were
continued for a total of 17 weeks, or 34 injections. For the duration of
the study, weights were recorded weekly and animals were monitored
for onset of disease. Additionally, plasma was collected every four weeks
to measure β-gal enzyme activity. Beginning at 24 weeks of age, mice
were subjected to a battery of behavioral tests to quantify neuromotor
and neurocognitive function. Twenty-four hours following the final in
jection, mice were euthanized, and tissues were collected. Study animals
were randomly selected to have the left hemisphere of the brain utilized
either for histopathological analysis or for measuring β-gal enzyme ac
tivity. Further, β-gal enzyme activity was measured in the liver, spleen,
kidney, and heart of all mice. For all animals, the right hemisphere of the
brain was microdissected to remove the hippocampus, cerebellum, and
cerebral cortex, which were utilized to measure ganglioside levels.
Overall, IV administration with mTfR-GLB1 was tolerated over the
duration of the study. At the end of the study, all female β-gal− /− mice
receiving mTfR-GLB1, except one mouse receiving the low dose, were
receiving prophylactic diphenhydramine. In contrast, only two male
β-gal− /− mice receiving the low dose and three receiving the high dose
were receiving prophylactic diphenhydramine. In most instances,
adverse reactions observed after administration of mTfR-GLB1 included
lethargy and respiratory changes. While all male mice in the experiment
survived, two female β-gal− /− mice were lost during the study. One
β-gal− /− female receiving vehicle only became emaciated nine weeks
into the study and required euthanasia. Post-mortem observations
revealed severe splenomegaly. The second mouse that was lost during

3.2. Long-term efficacy of mTfR-GLB1 in preventing disease onset in a
murine model of GM1-gangliosidosis
To test whether mTfR-GLB1 could prevent the onset of disease, mice
were treated for 17 weeks with twice weekly IV injections of mTfRGLB1, beginning at eight weeks of age. For this experiment, mice were
Table 1
Experimental design.
Group

Group designation

1
2
3
4

β-gal− /− , Baseline
Heterozygotes, Baseline
β-gal− /− , Vehicle only
Heterozygotes, Vehicle
only
β-gal− /− , Low dose
β-gal− /− , High dose

5
6

No. of animals

Total mTfR-GLB1 dose
(mg/kg)

Male

Female

3
3
8
8

3
3
8
8

0
0
0
0

8
8

8
8

2.5
5.0

4
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the study was a β-gal− /− mouse that was receiving a high dose of mTfRGLB1. This mouse became severely lethargic following mTfR-GLB1
administration and did not recover and a decision was made to eutha
nize the animal.

(Fig. 3C). However, in both mTfR-GLB1 treatment groups, β-gal enzyme
activity in the brain, heart, and kidney did not increase above vehicle
only β-gal− /− levels (Figs. 3D, E, F).
3.5. No reduction of ganglioside content in the brain of mTfR-GLB1
treated mice

3.3. Male β-gal− /− mice receiving high dose of mTfR-GLB1 are
significantly lighter than vehicle only β-gal− /− mice

To determine if long-term treatment of GM1-gangliosidosis mice
with mTfR-GLB1 reduced or prevented the accumulation of storage
material in the brain, GM1 and GA1 ganglioside levels were measured in
the cerebral cortex, cerebellum, and hippocampus (Fig. 4A, B, C). At
eight weeks of age, ganglioside levels in baseline β-gal− /− mice were
already significantly elevated compared to heterozygous β-gal+/− con
trols in all tissues assayed. Additionally, as the disease progressed be
tween two months of age when the study was initiated and the end of the
study at six months of age, ganglioside content increased 5–54% in the
cerebral cortex, 8–45% in the cerebellum, and 26–50% in the
hippocampus.
After 17 weeks of treatment, β-gal− /− mice treated with either the
low dose or high dose of mTfR-GLB1 showed no reduction in the
ganglioside content in the cerebral cortex, cerebellum, or hippocampus.
This further supports that mTfR-GLB1 does not cross the BBB as designed
or that the relatively low enzyme activity of the fusion protein is not
sufficient to reduce the substrate in the brain.

For the duration of the experiment, mice were weighed weekly prior
to the administration of the first dose of mTfR-GLB1. Previous charac
terization studies have shown that male β-gal− /− mice become signifi
cantly heavier than heterozygous and wildtype littermates [21]. In this
study, similar findings were observed, where the weights of female
β-gal− /− mice (Fig. 2A) were not significantly different than heterozy
gotes. Interestingly, throughout the study, the weights of male β-gal− /−
mice receiving the high dose of mTfR-GLB1 were lower than vehicle only
β-gal− /− mice, even significantly at various points throughout the study
(Fig. 2B). Further, the weights of male β-gal− /− mice that received the
low dose of mTfR-GLB1 trended lower than β-gal− /− mice receiving
vehicle only. Overall, there was an observable dose-weight response for
male β-gal− /− mice receiving mTfR-GLB1.
3.4. Presence of β-galactosidase enzyme activity in the liver and spleen of
β-gal− /− mice treated with mTfR-GLB1

3.6. Partial improvement of motor function in mice treated with mTfRGLB1

Plasma was first collected 24 h prior to the first administration of
mTfR-GLB1 and β-gal enzyme activity was measured. Plasma was then
collected every four weeks, 24 h after the second weekly injection. Both
groups receiving mTfR-GLB1 had no measurable increase in β-gal
enzyme activity over β-gal− /− mice receiving vehicle only at the time
points assessed (Fig. 3A). This further suggests that mTfR-GLB1 is
readily taken up into the peripheral tissues following IV administration.
At the conclusion of the study, β-gal enzyme activity was also
measured in multiple tissues, 24 h following the final administration of
mTfR-GLB1. In the liver, β-gal− /− mice receiving the low dose of mTfRGLB1 had 4.7-fold higher β-gal enzyme activity (9.76 ± 1.45 nmol/h/mg
protein) and mice that received the high dose of mTfR-GLB1 were 7.5fold higher (15.51 ± 2.69) compared to vehicle-treated β-gal− /− mice
(2.06 ± 0.13) (Fig. 3B). In the spleen, enzyme activity was also increased
2.4-fold (14.2 ± 1.66) in mice receiving the low dose and 5.0-fold
(29.63 ± 5.98) in mice receiving the high dose of mTfR-GLB1
compared to vehicle only β-gal− /− mice activity (5.93 ± 0.45)

At approximately 24 weeks of age, mice were subjected to a battery
of behavioral tests to assess whether treatment with mTfR-GLB1 could
improve neuromotor and neurocognitive function. To assess motor
function, specifically bradykinesia, the pole test was used. Both the low
and high dose groups had a significant improvement (p < 0.05 and p <
0.001, respectively) in their ability to coordinate their limbs and invert
their body on the pole, whereas the β-gal− /− mice receiving vehicle only
had extreme difficultly completing this task (Fig. 5A). Moreover, mice
receiving the high dose of mTfR-GLB1 had a significant reduction (p <
0.01) in the time it took to complete the entire task of turning and
descending the pole compared to vehicle-treated β-gal− /− mice
(Fig. 5B). Overall, there was an observed dose-response in the ability of
the mice to complete the pole test.
Additional testing was conducted to elucidate whether motor or

Fig. 2. Effects of mTfR-GLB1 on weight of β-gal− /− mice. For the duration of the study, the weights of (A) female mice and (B) male mice were measured and
recorded weekly. Mean ± SEM. All groups n = 8, except (A) Female β-gal− /− control and high dose (n = 7). *p < 0.05 when comparing high dose treated to vehicletreated β-gal− /− mice; **p < 0.01. Repeated-measures two-way ANOVA, followed by Tukey’s multiple comparisons test.
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Fig. 3. Plasma and tissue β-gal enzyme activity. (A) Plasma enzyme activity was measured prior to study initiation and 24-h following IV administration of mTfRGLB1 every four weeks for the duration of the study. For (B) to (F), mice were euthanized 24-h following the final treatment of mTfR-GLB1 (week 17), perfused with
phosphate buffered saline and tissues were collected and analyzed for β-gal enzyme activity as described in the materials and methods. Mean ± SEM. *p < 0.05 when
comparing treated to vehicle only β-gal− /− mice; **p < 0.01; ****p < 0.0001. (A) Repeated-measures two-way ANOVA, followed by Tukey’s multiple comparisons
test; (B)-(F) One-way ANOVA, followed by Dunnett’s multiple comparisons test.

Fig. 4. GM1 and GA1 ganglioside quantification in the brain of mice treated with mTfR-GLB1. Ganglioside levels were measured using high performance liquid
chromatography tandem-mass spectrometry in the (A) cerebral cortex, (B) cerebellum, and (C) hippocampus. Mean ± SEM. Two-way ANOVA, followed by Tukey’s
multiple comparisons test.

neurocognitive function was preserved in β-gal− /− mice treated with
mTfR-GLB1. To assess grip strength, the inverted screen was used. In this
test, β-gal− /− mice treated with mTfR-GLB1 showed no improvement in
their ability to remain on the inverted screen, performing similarly to
vehicle-treated β-gal− /− mice, suggesting that grip strength was not
maintained (Fig. 6A). Motor function and coordination were further
assessed using the accelerating rotarod. Similar to the inverted screen,
β-gal− /− mice treated with mTfR-GLB1 performed comparably to
vehicle-treated β-gal− /− mice (Fig. 6B).
To assess cognitive function, the Barnes maze was utilized. While
heterozygous β-gal+/− mice learned the task and escaped the platform in

under 60 s on the final testing day, vehicle-treated β-gal− /− mice failed
to learn the task. Similar to β-gal− /− mice receiving vehicle only, mice
treated with the low and high dose of mTfR-GLB1 failed to learn and
complete the task, exhibiting neurocognitive impairment (Fig. 6C).
3.7. Brain histopathological analysis revealed presence of severe neuronal
pathology in mice treated with mTfR-GLB1
When the mice were six months of age, the histology from the left
hemisphere of the brains was analyzed to determine whether mTfRGLB1 reduced or prevented the neuronal vacuolation described
6

M.J. Przybilla et al.

Molecular Genetics and Metabolism Reports 27 (2021) 100748

Fig. 5. Assessment of fine motor coordination using the pole test in mice receiving mTfR-GLB1. At six months of age, fine motor skills were tested using the pole test,
where animals were placed on a vertical pole facing upwards and the (A) time to invert and face downward was measured. Additionally, the (B) total time to
complete the inversion and descend the pole was measured. Mean ± SEM. *p < 0.05 when comparing treated to vehicle-treated β-gal− /− mice; **p < 0.01; ***p <
0.001. One-way ANOVA, followed by Dunnett’s multiple comparisons test.

Fig. 6. Further behavioral evaluation of motor and neurocognitive function of β-gal− /− mice treated with mTfR-GLB1. At six months of age, mice were subjected to
additional behavioral analyses. (A) Grip strength was assessed by placing mice on an inverted wire screen and timing the latency to fall. (B) Motor coordination was
tested using the accelerating rotarod, where the latency to fall is measured. (C) To assess neurocognitive function, mice were subjected to the Barnes maze, which
requires mice to learn to locate and escape the brightly-lit platform over the four day duration of the test. Mean ± SEM. (A) One-way ANOVA, followed by Dunnett’s
multiple comparisons test; (B and C) Repeated-measures two-way ANOVA, followed by Tukey’s multiple comparisons test.

previously. The brain tissue of vehicle-treated β-gal− /− mice had
neuronal lesions, consistent with the GM1-gangliosidosis phenotype
(Fig. 7B). This was characterized by swollen neurons that contained
clear to pale-eosinophilic, well-demarcated intracytoplasmic vacuoles,
occasional fine-granulation, displacement of the Nissl substance, and
occasional nuclear margination. These lesions are moderate to marked
and present in all areas of the brain, including the cerebellum, pons,
thalamus, hypothalamus, and cerebral cortex. In contrast, all of these
observations were absent from the heterozygous β-gal+/− brain tissue.
Further, the intracellular storage material in the affected neurons
stained positively with Luxol fast blue (Fig. 8B). Analysis of the brain
samples from β-gal− /− mice that received low (Fig. 7C) and high
(Fig. 7D) doses of mTfR-GLB1 for 17 weeks revealed the presence of
neuronal vacuolation that was comparable to that observed in β-gal− /−
mice receiving vehicle only. Further, similar to vehicle-treated β-gal− /−
mice, this intracellular storage material stained positively with Luxol
fast blue (Fig. 8C and D).

allows for the enzyme to bind to a receptor that is present on the
epithelial cells of the BBB and undergo receptor-mediated transcytosis.
The present study describes the assessment of such a protein, mTfRGLB1, as a potential therapy for GM1-gangliosidosis. mTfR-GLB1 fuses
the human β-gal enzyme to the carboxyl terminus of each heavy chain of
a mouse chimeric monoclonal antibody against the mouse transferrin
receptor, meaning there are two human β-gal enzymes present in each
molecule. The data presented shows that mTfR-GLB1 is cleared from the
bloodstream within 12 h following intravenous administration, as
demonstrated by the lack of β-gal enzyme activity in the plasma of
treated mice. mTfR-GLB1 has also been shown to be catalytically active
and capable of catabolizing the synthetic substrate 4-methylumbelliferyl
β-D-galactopyranoside used in β-gal enzyme assays, as shown by liver
and spleen enzyme activity. Additionally, weight measurements over
the duration of the study showed the weight of male β-gal− /− mice
receiving the high dose of mTfR-GLB1 was significantly lower than
β-gal− /− mice receiving vehicle only, displaying weights closer to that of
the heterozygous control group. Further, behavioral assessment at six
months of age using the pole test revealed improved motor function in
mice receiving the high dose of mTfR-GLB1.
At eight weeks of age, ganglioside content in β-gal− /− mice was
already elevated compared to normal heterozygous β-gal− /− mice.
Further, by the end of the study at six months of age, there was a pro
gressive accumulation of gangliosides as the disease advanced, dis
played by a significant increase in ganglioside content in six-month-old

4. Discussion
The treatment of lysosomal diseases with ERT using recombinant
native enzymes has been beneficial for thousands of patients suffering
from these diseases. However, these enzymes continue to lack neuro
logical benefit due to the inability of the lysosomal enzyme to cross the
BBB. To solve this problem, fusion enzymes have been developed, which
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Fig. 7. Neurological pathology in β-gal− /− mice treated with mTfR-GLB1. Hematoxylin and eosin staining of cerebellar tissue from the brain of six-month-old (A)
normal β-gal+/− mice, (B) vehicle-treated β-gal− /− mice, (C) β-gal− /− mice treated with 2.5 mg/kg of mTfR-GLB1 and (D) β-gal− /− mice treated with 5.0 mg/kg of
mTfR-GLB1. Arrows indicate examples of Purkinje neurons with intracytoplasmic vacuoles. Objective x60, scale bar indicates 50 μm.
Fig. 8. Luxol fast blue staining of intracellular stor
age material in mice treated with mTfR-GLB1. Luxol
fast blue staining of neurons in the cerebellum of sixmonth-old (A) heterozygous β-gal+/− mice, (B)
vehicle-treated β-gal− /− mice, (C) β-gal− /− mice
treated with 2.5 mg/kg of mTfR-GLB1 and (D)
β-gal− /− mice treated with 5.0 mg/kg of mTfR-GLB1.
Arrows illustrate Purkinje neurons with intra
cytoplasmic vacuoles that contain intracellular stor
age material stained positive with Luxol fast blue.
Objective x60, scale bar indicates 50 μm.

β-gal− /− mice receiving vehicle only. While this is the first observation
of ganglioside accumulation early in adulthood in the β-gal− /− model
used in this study, a similar result has been described in another murine
model of GM1-gangliosidosis [29–31]. Though treatment with mTfRGLB1 improved pole test results and mouse weight, full cognitive and
motor function was not improved. A possible interpretation of the
improved motor function in the pole test is that mTfR-GLB1 provided
enough β-gal enzyme activity to increase the physical activity of β-gal− /
−
mice. This increase in activity then could have contributed to the
observed weight reduction, which resulted in less of a burden on the
animals during a physical test such as inverting and descending a ver
tical pole. With significant ganglioside accumulation already present at
eight weeks of age, it is possible that even with therapeutic intervention
using mTfR-GLB1 or another approach, irreparable neurological damage

has been done and earlier treatment is necessary.
In contrast to biodistribution studies testing similar mTfR-lysosomal
enzyme fusion proteins, β-gal enzyme activity was not detected in the
heart, kidney, or brain of treated β-gal− /− mice at 12- and 24-h following
treatment. Prior studies with mTfR fused to IDUA have shown that IDUA
enzyme activity was increased in the heart, kidney, brain, liver, spleen,
and serum one hour following IV administration in IDUA-deficient mice
[13]. Further, brain ganglioside levels were not reduced in mTfR-GLB1
treated β-gal− /− mice compared to vehicle-treated β-gal− /− mice. In
another study, Boado et al. [16] showed that one week following the
final dose of a six-week treatment with the mTfR-lysosomal enzyme
fusion protein that heparan sulfate levels were significantly reduced in
the brain of MPS IIIB mice compared to sham-treated MPS IIIB mice.
Together, this data suggests mTfR-GLB1 has reduced biodistribution or a
8
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short half-life compared to these other mTfR-fusion enzymes.
Additionally, the absence of a therapeutic benefit in treating the
GM1-gangliosidosis pathology in β-gal− /− mice with mTfR-GLB1 can
potentially also be attributed to the instability of the human β-gal
enzyme. Human β-gal is known to form a dynamic multi-enzyme com
plex with neuraminidase 1 (NEU1) and protective protein cathepsin A
(PPCA) [32], which plays a role in intracellular stability of human β-gal.
Recently, Chen et al. [31] demonstrated that recombinant human β-gal
formed stable homodimers under acidic conditions at a concentration of
0.1 mg/ml, whereas at a neutral pH, the enzyme became unstable and
was predominantly found as a monomer. Further, while human β-gal
enzyme can be either in a multi-enzyme complex or as a homodimer, the
half-life is extended from a few hours to several days when in complex
with NEU1 and PPCA [33]. In cell culture experiments, β-gal-deficient
human fibroblasts transduced with retroviruses expressing human β-gal
[34] or transfected with plasmids expressing human β-gal [35] revealed
no or minimal β-gal enzyme activity in the cell culture media. Further,
Lambourne and Potter [35] showed that the catalytic activity of human
β-gal was dependent on temperature, showing reduced enzymatic ac
tivity at 37 ◦ C, which is the standard human biological temperature. In
contrast, the mouse β-gal enzyme provided higher enzyme activity in
β-gal-deficient human fibroblasts in cell lysates and the culture media
and was very thermostable [34,35].
In addition to the stability of the human β-gal enzyme, the lack of
therapeutic efficacy of mTfR-GLB1 could be due to the structure of the
mTfR-GLB1 protein. Studies have shown that the presence or location of
the receptor-binding component of the engineered enzyme can signifi
cantly impact enzyme activity, for example, in β-glucuronidase [23],
which is the deficient enzyme in the lysosomal disease MPS VII (Sly
syndrome), and β-galactosidase in GM1-gangliosidosis [9]. In vitro
studies showed that the synthetic mTfR-GLB1 enzyme, which is
comprised of two human β-gal enzymes, had 17% of the β-gal enzyme
activity as the recombinant human β-gal enzyme (unpublished data,
Tanabe Research Laboratories USA, Inc.). In the present murine study,
mice receiving the low and high dose of mTfR-GLB1 had approximately
12.5% and 20% of heterozygous levels of β-gal activity in the liver,
respectively. It was previously reported that approximately 1% of the
injected dose of the lysosomal enzyme fusion protein designed for MPS I
crosses the BBB [18]. However, with such a relatively low enzyme ac
tivity present in the peripheral tissue, measuring 1% of the injected dose
may be outside of the limits of detection of the β-gal enzyme assay. Even
so, if β-gal enzyme activity were measured in the brain, the present study
showed that long-term IV administration of mTfR-GLB1 at the current
doses provided limited benefits for preventing the onset of the GM1gangliosidosis phenotype and did not reduce ganglioside accumulation
in the brain. Recently, Boado et al. [24] re-designed and tested the
catalytic activity of a new human β-gal fusion enzyme. This enzyme,
termed HIRMAb-HC-LL-GLB1, includes a different linker (LL) sequence
between the β-gal enzyme and the monoclonal antibody against the
human insulin receptor (HIRMAb), compared to the mTfR-GLB1. This
modification resulted in the restoration of β-gal enzyme activity up to
93% of recombinant human β-gal enzyme activity [24]. Whether or not
this modification to increase β-gal enzyme activity results in a thera
peutic benefit for GM1-gangliosidosis has yet to be elucidated.
Overall, improved motor function in the pole test indicates a
response to therapy with mTfR-GLB1, but not sufficient to result in a
demonstrative improvement in the Barnes maze, accelerating rotarod,
and inverted screen. The association of animal weight with dose of
mTfR-GLB1, which may have contributed to improved motor abilities on
the pole test, suggests a possible dose-response effect. Administration of
mTfR-GLB1 was initiated after affected mice reached adulthood and
importantly, a profound pathologic accumulation of ganglioside was
shown to be present in the CNS of affected β-gal− /− mice prior to the age
of initiation of mTfR-GLB1 administration. Would dosing earlier in
disease course, when less neurological damage has occurred, allow for a
better therapeutic response? King et al. [3] has described a timeline of

clinical changes that occur in the infantile and juvenile gangliosidoses
through a clinical perspective natural history study. The gangliosidoses
are chronically progressive, but a critical window of time exists in which
the patients do not show overt signs of their gangliosidosis condition.
Children with the most severe infantile phenotype often appear healthy
at birth and have normal Agpar scores. Signs of neurological impairment
do not become apparent until four to six months of age, at which time
fine and gross motor skills markedly decline, leading parents and care
givers to seek a diagnosis. Cognitive abilities also begin to show decline
at this time or shortly thereafter [2]. Children with the classic juvenile
phenotype meet their first-year milestones. Signs of disease leading
caregivers to seek a diagnosis typically do not occur until after the third
to fifth year of life, and most often initially present as changes in
ambulation skills and language skills. In an intermediate form, the lateinfantile phenotype, patients meet first-year development milestones,
followed by appearance of marked changes in ambulation and language
skills [3]. Considering the severe and progressive neurological impair
ment that occurs in the gangliosidoses and concerns about irreversibility
of neurological damage, an effective therapy may require therapy
initiation to occur early, before disease symptoms are apparent. The
encouraging results of the pole test and observed weight normalization
in the high dose of mTfR-GLB1 suggest that such variations as a higher
dose, genetic modification of the fusion protein to accomplish higher
enzyme activity or earlier treatment with mTfR-GLB1 might elicit a
clearer therapeutic cognitive and motor skill improvement.
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